Evidence map›Paper›PMID 31420191›Full record

Trial reportKidney international2019

Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction.

Wendy McCallum, Hocine Tighiouart, Elaine Ku, Deeb Salem, Mark J Sarnak

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Kidney international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Taboo in cardiology: renin-angiotensin-aldosterone system antagonists worsening renal failure.European heart journal supplements : journal of the European Society of Cardiology · 2024
    Article
  14. Review
  15. Designing acute kidney injury clinical trials.Nature reviews. Nephrology · 2024
    Review
  16. Article
  17. Review
  18. Updates in Cardiorenal Syndrome.The Medical clinics of North America · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Wendy McCallumDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.
Hocine TighiouartInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA; Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts, USA.
Elaine KuDivision of Nephrology and Pediatric Nephrology, University of California San Francisco, San Francisco, California, USA.
Deeb SalemDivision of Cardiology and the CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.
Mark J SarnakDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA. Electronic address: msarnak@tuftsmedicalcenter.org.
Tufts Medical Center · USTufts University · USUniversity of California, San Francisco · US

Funding

Epidemiology, Clinical Trials and Outcomes Research In NephrologyT32DK007777 · NIDDK · TUFTS MEDICAL CENTER · PI SARNAK, MARK J · 1999 to 2020
$4.1M
Blood pressure trends, outcomes, and interventions in adolescents and young adults at increased cardiovascular riskK23HL131023 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KU, ELAINE · 2016 to 2020
$991k
NHLBI NIH HHS K23 HL131023NIDDK NIH HHS T32 DK007777
6 · The paper itself

Abstract

Angiotensin-converting enzyme inhibitors are beneficial in heart failure with reduced ejection fraction but are associated with acute declines in estimated glomerular filtration rate (eGFR). Prior studies evaluating thresholds of eGFR decline while using angiotensin-converting enzyme inhibitors in heart failure with reduced ejection have not taken into account this medication-driven decline. Here we used data from the Studies of Left Ventricular Dysfunction (SOLVD) trial of 6245 patients and performed Cox proportional hazards regression models to calculate hazard ratios of all-cause mortality and heart failure hospitalization-associated with percent eGFR decline at two- and six-weeks after randomization to enalapril versus placebo. In reference to placebo with equal degree of percent eGFR decline, any eGFR decline in the enalapril arm was associated with lower hazard of both outcomes. Under a conservative estimate using zero percent eGFR decline in the placebo arm as the reference, up to a 10% decline with enalapril was associated with mortality benefit (hazard ratio 0.87 [95% confidence interval 0.77, 0.99]) while up to a 35% decline was associated with decreased risk of heart failure hospitalization (0.78 [0.61, 0.98]). Under an intermediate estimate, up to a 15% decline with enalapril was associated with a mortality benefit (0.86 [0.77, 0.97]) and all levels of eGFR decline were associated with decreased risk of heart failure hospitalization. There was no percent eGFR decline, including up to 40%, in any models at either two- or six-weeks where enalapril was associated with higher mortality risk. Thus, in patients with reduced ejection fraction heart failure, enalapril is associated with decreased risk of mortality and heart failure hospitalizations. Hence, compelling reasons beyond moderate eGFR decline ought to be considered before its use is withdrawn.

Indexed as

AgedAngiotensin-Converting Enzyme InhibitorsEnalaprilFemaleGlomerular Filtration RateHeart FailureHospitalizationHumansMaleMiddle AgedUnited StatesAngiotensin-Converting Enzyme InhibitorsEnalaprilACE inhibitorcardiorenal syndromeheart failurekidney function declineSOLVD

Identifiers

PMID31420191
PMCPMC7392085
OpenAlexW2952242694

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.